sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
»ùÒòÐÞÊδ¹ÌåÁö¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > »ùÒòÐÞÊδ¹ÌåÁö¶¯ÎïÄ£×Ó

ǰÑÔ

´¹ÌåÁö(pituitary tumor)ÊÇÒ»ÖÖ³£¼ûµÄ­ÄÚÖ×Áö£¬Ô¼Õ¼Â­ÄÚÖ×ÁöµÄ10£¥~15£¥¡£´¹Ìå¿É·Ö³É´¹ÌåǰҶ£¨ÏÙ´¹Ì壩ºÍ´¹ÌåºóÒ¶£¨Éñ¾­´¹Ì壩Á½´ó²¿·Ö¡£´¹ÌåǰҶϸ°ûÉøÍ¸ÃÚÈéËØ(prolactin,PRL)¡¢´ÙÉöÉÏÏÙÆ¤Öʼ¤ËØ(adrenocorticotropic hormone,ACTH)¡¢ÂÑÅݴ̼¤ËØ(follicle stimulating hormone,FSH)ºÍÐþɫϸ°û´Ì¼¤ËØ(melanocyte stimulating hormone,MSH)µÈ¡£Éñ¾­´¹Ìå×Ô¼º²»ÖÆÔì¼¤ËØ£¬¶øÊÇÆðÒ»¸ö¿ÍÕ»µÄ×÷Óá£ÏÂÇðÄÔµÄÊÓÉϺ˺ÍÊÒÅÔºËÌìÉúµÄ¿¹ÀûÄò¼¤Ëغʹ߲úËØ£¬Í¨¹ýÏÂÇðÄÔÓë´¹ÌåÖ®¼äµÄÉñ¾­ÏËά±»Ë͵½Éñ¾­´¹ÌåÖü´æÆðÀ´£¬µ±ÉíÌåÐèҪʱ¾ÍÊͷŵ½ÑªÒºÖС£

´¹ÌåÁöÒÔǰҶµÄÏÙÁöÕ¼´ó´ó¶¼£¬À´×ÔºóÒ¶ÕßÉÙ¼û¡£´¹ÌåÁöµÄÖ¢×´ÌåÕ÷Ö÷ÒªÊÇÓÉÓÚÖ×ÁöµÄ¾Ö²¿Õ¥È¡£¬»ò¼¤ËØÉøÍ¸¹ý¶à£¬»òÒòÖÎÁÆÒýÆðµÄ¼¤ËØÉøÍ¸È±·¦¶øÌåÏÖ³öһϵÁеÄÁÙ´²ÌåÏÖ¡£Ö×Áöեȡ´¹ÌåÖÜΧ×éÖ¯ÌåÏÖΪһÁ¬ÐÔÍ·Í´£¬ÊÓ½»Ö¯¼°ÊÓÉñ¾­ÊøÕ¥È¡Ö¢£¬·ºÆðÊÓÁ¦¼õÍË¡¢ÊÓҰȱËðºÍÑ۵׸ıäµÈ¡£¼¤ËØÉøÍ¸Òì³£ÌåÏÖΪ¹¦Ð§ÐÔÖ×Áöϸ°ûÉøÍ¸¹ý¶à¼¤ËØ£¬ÈçÉú³¤¼¤Ëعý¶àÒýÆðÖ«¶Ë·Ê´óÖ¢£¬»òÎÞ¹¦Ð§ÐÔÖ×ÁöÔö´ó£¬ÆÆËðÕý³£´¹Ìå×é֯ʱÒýÆð¼¤ËØÉøÍ¸¹ýÉÙ£¬Èç´ÙÐÔÏÙ¼¤ËØÉøÍ¸ïÔÌ­¶ø±Õ¾­¡¢²»Óý»òÑôήµÈ¡£

´¹ÌåÁö¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ´¹ÌåÁöÄ£×Ó¡¢×Ô¾õÐÔ´¹ÌåÁöÄ£×Ó¡¢ÒÆÖ²ÐÔ´¹ÌåÁöÄ£×ÓÒÔ¼°»ùÒòÐÞÊδ¹ÌåÁöÄ£×ÓËÄÀà¡£ 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

SV40µÄT¿¹Ô­Ö°©»ùÒò¾ßÓкÜÇ¿µÄϸ°ûת»¯ÄÜÁ¦£¬ÒýÆðϸ°ûÈ¥·Ö½âÔöËٺͼ¤ËغϳÉïÔÌ­¡£T¿¹Ô­ÔÚ´¹Ìå´ÙÐÔÏÙϸ°ûµÄ±í´ïµ¼Ö´ÙÐÔÏÙ¼¤ËØÏ¸°ûµÄת»¯£¬ÐγÉÖ×Áö¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

½«5.5kbÃàÑòFSHβ»ùÒòÖбàÂë4.7kbµÄ5'²àÒíÐòÁУ¨º¬ÓÐÍâÏÔ×Ó1¡¢ÄÚº¬×Ó1ºÍÍâÏÔ×Ó2)ÖÁת¼Æðʼ²¿Î»¿Ë¡µ½º¬ÓÐSV40T¿¹Ô­µÄ´óTºÍСt±àÂëÇøµÄpBKCMVÔØÌåÄÚ£¬ÐγÉFSHβ-T¿¹Ô­ÈںϻùÒòƬ¶Ï£¬ÓÃÓÚÏÔ΢עÉ䣬ÖƱ¸ÑòFSHβ»ùÒòµÄµ÷ÀíÇøÓòÖ±½Ó±í´ïSV40T¿¹Ô­Ö°©»ùÒòµÄת»ùÒò´¹ÌåÁöСÊóÄ£×Ó¡£

¡¾Ä£×ÓÌØµã¡¿£º

¾ßÓÐÕâÖÖÈںϻùÒòµÄ2/5ת»ùÒòСÊóϵѸËÙ±¬·¢´¹ÌåÁö£¬6ÖÜÁäʱ·ºÆðÏÙÁöÑùÂËÅÝ£¬êòĵÐÔÔÚ12ÖÜÁäʱéæÃü¡£×é֯ѧ¼ì²éÏÔʾϸ°ûµÄÔöÉúÔöÌíÅãͬ×Å·¢Óý²»È«ÊÇÓÉ´¹Ìå¼¤ËØºÏ³ÉµÄïÔÌ­£¬Åú×¢´¹Ìåϸ°û´¦ÓÚÈ¥·Ö½â״̬£¬Ã»ÓдÙÐÔÏÙ¼¤ËØºÍÆäËû´¹Ìå¼¤ËØµÄ±í´ï¡£Ö×ÁöÆðÔ´³Ê¶à²¡Ô¿É¼û¸ß¶Èת»¯µÄÖØ´óµ­È¾ÊȼîÐÔϸ°û£¬ÓÐÖÚ¶à¶à±¶ºË£¬°éÓÐÉñ¾­ÔªÑùϸ°û½þÈó£¬ÔÚÖ×ÁöÉú³¤µÄ×îºó½×¶ÎÕâÖÖϸ°ûºÜÊǶà¡£ÓÐË¿·ÖÀàÖ¸ÊýÔÚת»ùÒòµÄ´¹ÌåÖкÜÊǸß¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

´ËÄ£×ÓµÄÑо¿ÓÐÖúÓÚÏàʶ´¹ÌåÖ×ÁöÐγɵÄÐÄÀíºÍ·Ö×Ó»úÖÆ¡£

 

²Î¿¼ÎÄÏ×£º

1.ÕÅÃÍ£¬ÕÅÇïÉú£¬ÁÖºãÖÝ£¬µÈ. ÒÒÏ©´Æ·ÓÓÕµ¼µÄ´óÊó´¹ÌåÁöÄ£×ӵĽ¨É裮Öйú²¡ÀíÐÄÀíÔÓÖ¾£¬2012, 28 (8): 1532-1536

2.Helseth A, Siegal GP, Haug E, et al Transgenic mice that develop pituitary tumors. A model for Cushing's disease£®Am J Pathol, 1992, 140 (5):1071-1080

3.Cristina C, Garc í a-Tornad ú I, D í az-Torga G, et al.Doparninergic 02 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res, 2006, 35: 50-63

4.Ishii J, Kawakami Y. Recent progress in experimental pituitary tumors in various animals. Nihon Rinsho, 1993, 51 (10):2580-2584

5.Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene,2002,21 (20):3190-3198

6.Pernasetti F, Spacly TJ, Hall SB,et al. Pituitary turnorigenesi targeted by the ovine follicle-stimulating hormone beta­subunit gene regulatory region in transgenic mice. Mol Cell Endocrinol, 2003,203 (1-2): 169-183

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > ÄÚÉøÍ¸¼°´úлÐÔ¼²²¡Ä£×Ó > »ùÒòÐÞÊδ¹ÌåÁö¶¯ÎïÄ£×Ó
»ùÒòÐÞÊδ¹ÌåÁö¶¯ÎïÄ£×Ó

ǰÑÔ

´¹ÌåÁö(pituitary tumor)ÊÇÒ»ÖÖ³£¼ûµÄ­ÄÚÖ×Áö£¬Ô¼Õ¼Â­ÄÚÖ×ÁöµÄ10£¥~15£¥¡£´¹Ìå¿É·Ö³É´¹ÌåǰҶ£¨ÏÙ´¹Ì壩ºÍ´¹ÌåºóÒ¶£¨Éñ¾­´¹Ì壩Á½´ó²¿·Ö¡£´¹ÌåǰҶϸ°ûÉøÍ¸ÃÚÈéËØ(prolactin,PRL)¡¢´ÙÉöÉÏÏÙÆ¤Öʼ¤ËØ(adrenocorticotropic hormone,ACTH)¡¢ÂÑÅݴ̼¤ËØ(follicle stimulating hormone,FSH)ºÍÐþɫϸ°û´Ì¼¤ËØ(melanocyte stimulating hormone,MSH)µÈ¡£Éñ¾­´¹Ìå×Ô¼º²»ÖÆÔì¼¤ËØ£¬¶øÊÇÆðÒ»¸ö¿ÍÕ»µÄ×÷Óá£ÏÂÇðÄÔµÄÊÓÉϺ˺ÍÊÒÅÔºËÌìÉúµÄ¿¹ÀûÄò¼¤Ëغʹ߲úËØ£¬Í¨¹ýÏÂÇðÄÔÓë´¹ÌåÖ®¼äµÄÉñ¾­ÏËά±»Ë͵½Éñ¾­´¹ÌåÖü´æÆðÀ´£¬µ±ÉíÌåÐèҪʱ¾ÍÊͷŵ½ÑªÒºÖС£

´¹ÌåÁöÒÔǰҶµÄÏÙÁöÕ¼´ó´ó¶¼£¬À´×ÔºóÒ¶ÕßÉÙ¼û¡£´¹ÌåÁöµÄÖ¢×´ÌåÕ÷Ö÷ÒªÊÇÓÉÓÚÖ×ÁöµÄ¾Ö²¿Õ¥È¡£¬»ò¼¤ËØÉøÍ¸¹ý¶à£¬»òÒòÖÎÁÆÒýÆðµÄ¼¤ËØÉøÍ¸È±·¦¶øÌåÏÖ³öһϵÁеÄÁÙ´²ÌåÏÖ¡£Ö×Áöեȡ´¹ÌåÖÜΧ×éÖ¯ÌåÏÖΪһÁ¬ÐÔÍ·Í´£¬ÊÓ½»Ö¯¼°ÊÓÉñ¾­ÊøÕ¥È¡Ö¢£¬·ºÆðÊÓÁ¦¼õÍË¡¢ÊÓҰȱËðºÍÑ۵׸ıäµÈ¡£¼¤ËØÉøÍ¸Òì³£ÌåÏÖΪ¹¦Ð§ÐÔÖ×Áöϸ°ûÉøÍ¸¹ý¶à¼¤ËØ£¬ÈçÉú³¤¼¤Ëعý¶àÒýÆðÖ«¶Ë·Ê´óÖ¢£¬»òÎÞ¹¦Ð§ÐÔÖ×ÁöÔö´ó£¬ÆÆËðÕý³£´¹Ìå×é֯ʱÒýÆð¼¤ËØÉøÍ¸¹ýÉÙ£¬Èç´ÙÐÔÏÙ¼¤ËØÉøÍ¸ïÔÌ­¶ø±Õ¾­¡¢²»Óý»òÑôήµÈ¡£

´¹ÌåÁö¶¯ÎïÄ£×Ó¿É·ÖΪÓÕ·¢ÐÔ´¹ÌåÁöÄ£×Ó¡¢×Ô¾õÐÔ´¹ÌåÁöÄ£×Ó¡¢ÒÆÖ²ÐÔ´¹ÌåÁöÄ£×ÓÒÔ¼°»ùÒòÐÞÊδ¹ÌåÁöÄ£×ÓËÄÀà¡£ 

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯ÎСÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

SV40µÄT¿¹Ô­Ö°©»ùÒò¾ßÓкÜÇ¿µÄϸ°ûת»¯ÄÜÁ¦£¬ÒýÆðϸ°ûÈ¥·Ö½âÔöËٺͼ¤ËغϳÉïÔÌ­¡£T¿¹Ô­ÔÚ´¹Ìå´ÙÐÔÏÙϸ°ûµÄ±í´ïµ¼Ö´ÙÐÔÏÙ¼¤ËØÏ¸°ûµÄת»¯£¬ÐγÉÖ×Áö¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

½«5.5kbÃàÑòFSHβ»ùÒòÖбàÂë4.7kbµÄ5'²àÒíÐòÁУ¨º¬ÓÐÍâÏÔ×Ó1¡¢ÄÚº¬×Ó1ºÍÍâÏÔ×Ó2)ÖÁת¼Æðʼ²¿Î»¿Ë¡µ½º¬ÓÐSV40T¿¹Ô­µÄ´óTºÍСt±àÂëÇøµÄpBKCMVÔØÌåÄÚ£¬ÐγÉFSHβ-T¿¹Ô­ÈںϻùÒòƬ¶Ï£¬ÓÃÓÚÏÔ΢עÉ䣬ÖƱ¸ÑòFSHβ»ùÒòµÄµ÷ÀíÇøÓòÖ±½Ó±í´ïSV40T¿¹Ô­Ö°©»ùÒòµÄת»ùÒò´¹ÌåÁöСÊóÄ£×Ó¡£

¡¾Ä£×ÓÌØµã¡¿£º

¾ßÓÐÕâÖÖÈںϻùÒòµÄ2/5ת»ùÒòСÊóϵѸËÙ±¬·¢´¹ÌåÁö£¬6ÖÜÁäʱ·ºÆðÏÙÁöÑùÂËÅÝ£¬êòĵÐÔÔÚ12ÖÜÁäʱéæÃü¡£×é֯ѧ¼ì²éÏÔʾϸ°ûµÄÔöÉúÔöÌíÅãͬ×Å·¢Óý²»È«ÊÇÓÉ´¹Ìå¼¤ËØºÏ³ÉµÄïÔÌ­£¬Åú×¢´¹Ìåϸ°û´¦ÓÚÈ¥·Ö½â״̬£¬Ã»ÓдÙÐÔÏÙ¼¤ËØºÍÆäËû´¹Ìå¼¤ËØµÄ±í´ï¡£Ö×ÁöÆðÔ´³Ê¶à²¡Ô¿É¼û¸ß¶Èת»¯µÄÖØ´óµ­È¾ÊȼîÐÔϸ°û£¬ÓÐÖÚ¶à¶à±¶ºË£¬°éÓÐÉñ¾­ÔªÑùϸ°û½þÈó£¬ÔÚÖ×ÁöÉú³¤µÄ×îºó½×¶ÎÕâÖÖϸ°ûºÜÊǶà¡£ÓÐË¿·ÖÀàÖ¸ÊýÔÚת»ùÒòµÄ´¹ÌåÖкÜÊǸß¡£

¡¾Ä£×ӵįÀ¹ÀºÍÓ¦Óá¿£º

´ËÄ£×ÓµÄÑо¿ÓÐÖúÓÚÏàʶ´¹ÌåÖ×ÁöÐγɵÄÐÄÀíºÍ·Ö×Ó»úÖÆ¡£

 

²Î¿¼ÎÄÏ×£º

1.ÕÅÃÍ£¬ÕÅÇïÉú£¬ÁÖºãÖÝ£¬µÈ. ÒÒÏ©´Æ·ÓÓÕµ¼µÄ´óÊó´¹ÌåÁöÄ£×ӵĽ¨É裮Öйú²¡ÀíÐÄÀíÔÓÖ¾£¬2012, 28 (8): 1532-1536

2.Helseth A, Siegal GP, Haug E, et al Transgenic mice that develop pituitary tumors. A model for Cushing's disease£®Am J Pathol, 1992, 140 (5):1071-1080

3.Cristina C, Garc í a-Tornad ú I, D í az-Torga G, et al.Doparninergic 02 receptor knockout mouse: an animal model of prolactinoma. Front Horm Res, 2006, 35: 50-63

4.Ishii J, Kawakami Y. Recent progress in experimental pituitary tumors in various animals. Nihon Rinsho, 1993, 51 (10):2580-2584

5.Fedele M, Battista S, Kenyon L, et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene,2002,21 (20):3190-3198

6.Pernasetti F, Spacly TJ, Hall SB,et al. Pituitary turnorigenesi targeted by the ovine follicle-stimulating hormone beta­subunit gene regulatory region in transgenic mice. Mol Cell Endocrinol, 2003,203 (1-2): 169-183

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿